Form 4: Myriad Genetics Director Paul Bisaro Granted Over 49,000 Restricted Stock Units

Myriad Genetics Inc. Director Paul Bisaro was granted 49,796 restricted stock units, increasing his beneficial ownership to 89,941 shares, aligning his interests with shareholders.

Summary

• Paul Bisaro, a Director of Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock in the form of restricted stock units (RSUs) on June 5, 2025.
• These RSUs were granted at a price of $0 per unit, indicating they are part of a compensation package.
• The RSUs were issued pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are set to vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.
• Following this transaction, Mr. Bisaro's total beneficial ownership in Myriad Genetics Inc. stands at 89,941 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates alignment of a director's interests with shareholders through equity compensation, a standard and healthy corporate governance practice. It does not, however, signal any extraordinary operational or financial performance.

Positives

• The grant of restricted stock units to Director Paul Bisaro aligns his financial interests more closely with those of the company's shareholders, as the value of his compensation is tied to the company's stock performance.
• The transaction demonstrates the company's commitment to its equity incentive plan, which is a common method for attracting and retaining qualified directors and employees.

Future Outlook

The acquired restricted stock units are expected to vest upon the earlier of June 5, 2026 (one year from grant date) or the date of the next annual meeting of stockholders following the grant, at which point they will convert into common stock.

Industry Context

The granting of restricted stock units (RSUs) to directors is a standard practice in the biotechnology and diagnostics industry, including the genetics sector, as a form of non-cash compensation. This method is widely used to incentivize long-term commitment and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of director compensation is a common practice across the S&P 500 and particularly prevalent in the life sciences and technology sectors, including companies like Illumina (ILMN) and Exact Sciences (EXAS), which also utilize equity-based incentives to attract and retain top talent and align management with long-term shareholder interests.
• The vesting schedule, typically over one year or until the next annual meeting, is also standard for director RSU grants, ensuring continued engagement and oversight.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Paul Bisaro, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board. This is a standard and disclosed form of compensation under the company's equity incentive plan.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders, as his compensation value is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees/Consultants: The reference to the 2017 Equity Incentive Plan suggests a broader framework for equity compensation that benefits other employees and consultants, fostering a sense of ownership and long-term commitment across the organization.

Next Steps

• The restricted stock units will vest upon the earlier of June 5, 2026, or the date of Myriad Genetics' next annual meeting of stockholders, at which point they will convert into common stock.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, Paul Bisaro, Director, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Incentive Plan, Compensation